Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,166.9
-13.7 (-0.43%)

 

  • STI Straits Times Index
    3,166.9
    -13.7 (-0.43%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,494.6
    -18.3 (-1.21%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,961.0
    -354.3 (-1.35%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,397.4
    -14.4 (-0.42%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    27,283.6
    -498.8 (-1.80%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,070.0
    -50.7 (-0.83%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,329.7M
  • Value: 1,564.3M
  • Rise: 137
  • Fall: 185
  • Unch: 438

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Sembcorp Marine0.115+0.007
Hong Lai Huat0.107+0.003
RH PetroGas0.175-0.007
Singtel2.270-0.010
Shen Yao0.006-0.001
Golden Agri-Res0.230-0.005
CapLand IntCom T2.150+0.010
Genting Sing0.810-0.010
Mercurius0.061-
GKE0.146-0.007

World Indices

World Indices
Name Last Change
Nasdaq 14,672.7 -105.6
HSI 25,961.0
HSCEI 9,233.2
Jakarta 6,070.0
Nikkei 225 27,283.6
SSE Comp 3,397.4
Shanghai A 3,560.7
Shanghai B 254.0
KOSPI 3,202.3

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

JOHNSON & JOHNSON JOHNSON & JOHNSON
Updated on 30 Jul 2021 (End of trading day)
Last (USD): 172.200 Change: +0.020 High: 172.980 Remarks: -
Change (%): +0.01 Low: 171.840
Open 172.540 Yesterday's Close 172.17999999999998
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 5,346,332 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a 5.58941 Trailing EPS (USD) e 6.74915 NAV (USD) b 26.4313
PE a 30.808 Trailing PE f 25.514 Price / NAV b 6.5150
Dividend (USD) d 3.980048 Cash In Hand (USD) g 5.4443 Issued & Paid-up Shares c 2,632,480,000
Dividend Yield (%) d 2.311 Price / Cash In Hand g 31.629 Treasury Shares h 487,141,000
Market Cap (M) 453,313.056 Enterprise Value (M) 461,490.056
Piotroski F Score 1 Exchange Code JNJ Par Value ( $ ) n.a.
52 Weeks Volatility (%) 15.85 Free Float (%) -
Sector & Industry Health Technology - Pharmaceuticals: Major
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 30 Jul 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 04 May 2021.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference JOHNSON & JOHNSON NYSE 453,313.056 30.808 25.514 6.5150 2.311
Industry Pharmaceuticals: Major NYSE 120,202.983 34.090 29.051 10.1404 1.995
Local Peer PFIZER INC NYSE 239,637.109 24.921 18.116 - 3.554
Local Peer ELI LILLY AND COMPANY NYSE 233,522.831 37.703 38.330 33.8505 1.213
Local Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 224,916.064 27.698 25.007 4.1619 2.086
Local Peer ABBVIE INC NYSE 205,411.386 45.086 40.403 14.9827 4.159
Local Peer MERCK & CO INC NYSE 194,639.452 27.542 48.346 - 3.224
Local Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 164,139.056 25.472 24.416 17.7561 1.453
Local Peer BRISTOL-MYERS SQUIBB CO NYSE 150,814.606 - - 4.0973 2.738
Local Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 100,985.818 13.698 17.026 4.7540 5.155
Local Peer TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS NYSE 52,214.415 14.728 14.728 1.1162 4.644
Local Peer BIOHAVEN PHARMACEUTICAL HLDG CO LTD NYSE 8,199.962 - - -29.7123 -
Local Peer ORGANON & CO NYSE 7,354.499 3.405 3.405 1.5575 -
Local Peer EMERGENT BIOSOLUTIONS INC NYSE 3,531.284 11.574 11.987 - -
Other Local Peers ADC THERAPEUTICS SA (NYSE), AMNEAL PHARMACEUTICALS INC (NYSE), ZYMEWORKS INC (NYSE), LANNETT CO INC (NYSE)
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 177,342.685 55.061 54.624 - 2.028
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 130,276.652 9.281 36.392 - 2.594
Global Peer WUXI APPTEC HKEx 510,950.397 153.950 107.255 12.2061 0.203
Global Peer ROYALTY PHARMA PLC NASDAQ 23,191.678 23.785 23.840 4.7502 0.502
Global Peer HANSOH PHARMA HKEx 164,937.448 57.138 57.138 7.7822 0.277
Global Peer VIATRIS INC NASDAQ 17,005.846 - - 0.7941 -
Global Peer INNOVENT BIO HKEx 115,582.163 - - 11.1033 -
Global Peer CANSINOBIO-B HKEx 111,014.141 - - 15.4429 -
Global Peer REPLIGEN CORP NASDAQ 13,507.898 225.409 135.170 8.4263 -
Global Peer CUREVAC NV NASDAQ 9,173.197 - - - -
Other Global Peers SINOPHARM (HKEx), HUTCHMED (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), REMEGEN-B (HKEx), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), HYGEIA HEALTH (HKEx), JUNSHI BIO (HKEx), SH PHARMA (HKEx), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), AKESO-B (HKEx), APELLIS PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), INNOCARE-B (HKEx), REATA PHARMACEUTICALS INC (NASDAQ), BAIYUNSHAN PH (HKEx), ALLAKOS INC (NASDAQ), IMMUNITYBIO INC (NASDAQ), SPRINGWORKS THERAPEUTICS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), CHINARES PHARMA (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), SIMCERE PHARMA (HKEx), TRAD CHI MED (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), NEKTAR THERAPEUTICS (NASDAQ), CHINAGRANDPHARM (HKEx), ERASCA INC (NASDAQ), ATAI LIFE SCIENCES NV (NASDAQ), OPKO HEALTH INC (NASDAQ), EVEREST MED-B (HKEx), HENLIUS (HKEx), IGM BIOSCIENCES INC (NASDAQ), CSTONE PHARMA-B (HKEx), CARSGEN-B (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), SSY GROUP (HKEx), QUANTERIX CORPORATION (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HEPALINK (HKEx), OCUMENSION-B (HKEx), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), NURIX THERAPEUTICS INC (NASDAQ), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), UNITED LAB (HKEx), REPARE THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ANTENGENE-B (HKEx), TONGRENTANGCM (HKEx), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), KRONOS BIO INC (NASDAQ), IMMUNOTECH-B (HKEx), Kimia Farma Tbk. (IDX), FORMA THERAPEUTICS HLDGS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), KINIKSA PHARMACEUTICALS LTD (NASDAQ), MIND MEDICINE (MINDMED) INC (NASDAQ), PETIQ INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), CKLIFE SCIENCES (HKEx), CULLINAN ONCOLOGY INC (NASDAQ), SCICLONE PHARMA (HKEx), GH RESEARCH PLC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ICOSAVAX INC (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), OCULAR THERAPEUTIX INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), ANNEXON INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), SHINEWAY PHARM (HKEx), AKERO THERAPEUTICS INC (NASDAQ), POINT BIOPHARMA GLOBAL INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), ALPHA TEKNOVA INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), ORIC PHARMACEUTICALS INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), EVOLUS INC (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), TENAYA THERAPEUTICS INC (NASDAQ), ACUMEN PHARMACEUTICALS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), PHARVARIS NV (NASDAQ), ZHAOKE OPHTH-B (HKEx), VERU INC (NASDAQ), AC IMMUNE SA (NASDAQ), CLENE INC (NASDAQ), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), HUA MEDICINE-B (HKEx), KALVISTA PHARMACEUTICALS INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), WEREWOLF THERAPEUTICS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), Soho Global Health Tbk. (IDX), TARSUS PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), IGBB (Bursa), ATHENEX INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), INOZYME PHARMA INC (NASDAQ), PROVENTION BIO INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), BIOMEA FUSION INC (NASDAQ), ALZAMEND NEURO INC (NASDAQ), BEYONDSPRING INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), RACE ONCOLOGY LTD (ASX), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), AFT PHARMACEUTICALS LTD (ASX), GRITSTONE BIO INC (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), DURECT CORP (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), 89BIO INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), TOT BIOPHARM-B (HKEx), GAMIDA CELL LTD (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), BSTEAD (Bursa), CLEARSIDE BIOMEDICAL INC (NASDAQ), ANNOVIS BIO INC (NYSE American), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), SOL GEL TECHNOLOGIES LTD (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), PHARMA (Bursa), OVID THERAPEUTICS INC (NASDAQ), MUSTANG BIO INC (NASDAQ), FUSEN PHARM (HKEx), NEXIMMUNE INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), HARROW HEALTH INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), VINCERX PHARMA INC (NASDAQ), IMMUNIC INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), OBSEVA SA (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), RENEO PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), IP (SET), TRICIDA INC (NASDAQ), CH BIOTECH SER (HKEx), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), POLYPID LTD (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), IMARA INC (NASDAQ), ZHONGZHIPHARM (HKEx), GENPREX INC (NASDAQ), VYNE THERAPEUTICS INC (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), IX Biopharma (SGX), ETON PHARMACEUTICALS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), ENTERA BIO LTD (NASDAQ), NOVAN INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), REGENCELL BIOSCIENCE HLDGS LTD (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), EYENOVIA INC (NASDAQ), PROPHASE LABS INC (NASDAQ), GALECTO INC (NASDAQ), MEDIWOUND LTD (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), AYTU BIOPHARMA INC (NASDAQ), TEMPEST THERAPEUTICS INC (NASDAQ), CRESO PHARMA LTD (ASX), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), NEW RAY MEDIC (HKEx), CHARMACY PHAR (HKEx), APREA THERAPEUTICS INC (NASDAQ), PROTARA THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), GRAYBUG VISION INC (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), KOTRA (Bursa), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), NC HEALTHCARE (HKEx), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), Phapros Tbk. (IDX), PAK FAH YEOW (HKEx), ALLENA PHARMACEUTICALS INC (NASDAQ), Hyphens Pharma (SGX), EDESA BIOTECH INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), NOVA (Bursa), INVION LTD (ASX), MODERN CHI MED (HKEx), BIOHLDG (Bursa), BRICKELL BIOTECH INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), EXOPHARM LTD (ASX), ASSERTIO HOLDINGS INC (NASDAQ), MANNATECH INC (NASDAQ), ACURX PHARMACEUTICALS INC (NASDAQ), NEP INTERLONG (HKEx), UNIVERSE PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), VIRIOS THERAPEUTICS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), WAI YUEN TONG (HKEx), SYNAPTOGENIX INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), PALLA PHARMA LTD (ASX), TBG DIAGNOSTICS LTD (ASX), CNS PHARMACEUTICALS INC (NASDAQ), TELIGENT INC NEW (NASDAQ), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), PURAPHARM (HKEx), ACER THERAPEUTICS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), SANAI HEALTH GP (HKEx), EXTRAWELL PHAR (HKEx), PANBELA THERAPEUTICS INC (NASDAQ), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), PHARMAXIS (ASX), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), HOTH THERAPEUTICS INC (NASDAQ), SUNZEN (Bursa), NLS PHARMACEUTICS LTD (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), PAINREFORM LTD (NASDAQ), TALI DIGITAL LIMITED (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), IMMURON LIMITED (ASX), ACRUX (ASX), TITAN PHARMACEUTICAL INC (NASDAQ), VIRPAX PHARMA INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), SUDA PHARMACEUTICALS LTD (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), FIJI KAVA LTD (ASX), FARMAFORCE LTD (ASX), Pharmesis Intl (SGX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days -+0.410
+0.24 %
10 Days -+4.100
+2.44 %
20 Days -+3.220
+1.91 %
Medium Term Return 3 Months -+9.470
+5.82 %
6 Months 1.010+9.070
+6.18 %
1 Year 227.250+26.440
+174.05 %
Long Term Return 2 Years 231.110+41.130
+207.71 %
3 Years 234.760+40.250
+208.42 %
5 Years 241.420+47.960
+232.92 %
Annualised Return Annualised --
+27.19 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 133.650 - 173.650 Change From 1 Year Low +38.550 % Change From 1 Year Low (%) +28.84
Change From 1 Year High -1.450 % Change From 1 Year High (%) -0.84
2 Years Range 109.160 - 173.650 Change From 2 Years Low +63.040 % Change From 2 Years Low (%) +57.75
Change From 2 Years High -1.450 % Change From 2 Years High (%) -0.84
5 Years Range 109.160 - 173.650 Change From 5 Years Low +63.040 % Change From 5 Years Low (%) +57.75
Change From 5 Years High -1.450 % Change From 5 Years High (%) -0.84
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular & neurovascular, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Historical Price Data

Date Open High Low Close Volume VWAP
30 Jul 2021 172.540 172.980 171.840 172.200 5,346,332 -
29 Jul 2021 172.740 173.340 171.085 172.180 4,212,956 -
28 Jul 2021 172.730 173.380 172.080 172.180 5,750,588 -
27 Jul 2021 171.800 172.720 170.670 172.660 7,087,712 -
26 Jul 2021 171.820 172.140 170.862 171.870 4,484,830 -
23 Jul 2021 171.000 172.175 170.380 171.790 5,014,867 -
22 Jul 2021 169.360 171.070 168.650 169.980 5,281,109 -
21 Jul 2021 169.300 169.690 167.480 169.490 7,585,018 -
20 Jul 2021 166.900 170.810 166.840 168.450 9,895,700 -
19 Jul 2021 166.480 168.190 165.320 166.880 8,218,836 -
16 Jul 2021 168.340 169.090 167.950 168.100 5,834,690 -
15 Jul 2021 169.300 169.900 167.720 168.370 6,655,345 -
14 Jul 2021 170.000 170.830 169.040 170.420 6,153,825 -
13 Jul 2021 168.970 169.755 168.672 169.270 4,689,881 -
12 Jul 2021 169.730 171.180 168.540 169.480 7,832,778 -
09 Jul 2021 169.370 170.370 169.240 169.750 6,119,847 -
08 Jul 2021 168.700 169.460 167.580 169.080 5,755,445 -
07 Jul 2021 167.480 169.500 167.480 169.410 6,293,374 -
06 Jul 2021 167.910 168.860 166.990 167.970 6,097,457 -
02 Jul 2021 166.020 169.300 165.640 168.980 9,059,270 -
01 Jul 2021 164.740 166.010 164.630 165.960 6,317,618 -
30 Jun 2021 164.000 164.970 163.670 164.740 6,149,715 -
Summary
Current 2 Weeks
(19 Jul 2021 to 30 Jul 2021)
166.480 173.380 165.320 172.200 62,877,948 -
Previous 2 Weeks
(02 Jul 2021 to 16 Jul 2021)
166.020 173.380 165.320 168.100 64,491,912 -
4 Weeks from
(04 Jun 2021 to 01 Jul 2021)
167.005 173.380 165.320 165.960 128,853,031 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.